Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
26
USD
|
+0.19%
|
|
-0.31%
|
+95.49%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
954.3
|
606
|
604.1
|
816.3
|
2,272
|
-
|
-
|
Enterprise Value (EV)
1 |
609
|
229.5
|
348.1
|
693.2
|
2,081
|
1,970
|
2,096
|
P/E ratio
|
-5.08
x
|
-4.06
x
|
-3.59
x
|
-3.37
x
|
-8.38
x
|
-7.94
x
|
-8.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
162
x
|
45
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
140
x
|
41.5
x
|
EV / EBITDA
|
-10.5
x
|
-1.54
x
|
-2.06
x
|
-2.88
x
|
-6.64
x
|
-6.73
x
|
-6.25
x
|
EV / FCF
|
-12.8
x
|
-1.86
x
|
-2.22
x
|
-3.67
x
|
-8.81
x
|
-8.02
x
|
-8.85
x
|
FCF Yield
|
-7.83%
|
-53.7%
|
-45%
|
-27.2%
|
-11.3%
|
-12.5%
|
-11.3%
|
Price to Book
|
2.79
x
|
1.67
x
|
2.39
x
|
8.7
x
|
8.52
x
|
6.32
x
|
-
|
Nbr of stocks (in thousands)
|
45,445
|
50,970
|
52,124
|
61,376
|
87,383
|
-
|
-
|
Reference price
2 |
21.00
|
11.89
|
11.59
|
13.30
|
26.00
|
26.00
|
26.00
|
Announcement Date
|
3/4/21
|
3/10/22
|
3/2/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
14.06
|
50.51
|
EBITDA
1 |
-
|
-57.95
|
-148.9
|
-169.3
|
-240.5
|
-313.5
|
-293
|
-335.2
|
EBIT
1 |
-
|
-58.65
|
-150
|
-171
|
-242.2
|
-275.5
|
-306
|
-315.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,177.05%
|
-624.03%
|
Earnings before Tax (EBT)
1 |
-
|
-59.44
|
-149.3
|
-168.1
|
-235.9
|
-261.5
|
-317
|
-380
|
Net income
1 |
-14.86
|
-59.44
|
-149.3
|
-168.1
|
-235.9
|
-259
|
-292.3
|
-295.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,079.08%
|
-585.55%
|
EPS
2 |
-1.830
|
-4.130
|
-2.930
|
-3.230
|
-3.950
|
-3.103
|
-3.276
|
-2.998
|
Free Cash Flow
1 |
-
|
-47.67
|
-123.2
|
-156.7
|
-188.9
|
-236.2
|
-245.7
|
-236.8
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,747.48%
|
-468.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/25/20
|
3/4/21
|
3/10/22
|
3/2/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-51.62
|
-35.36
|
-52.3
|
-41.88
|
-39.74
|
-45.05
|
-66.3
|
-61.84
|
-67.29
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-51.96
|
-35.78
|
-52.76
|
-42.28
|
-40.15
|
-45.46
|
-66.74
|
-62.27
|
-67.69
|
-69.16
|
-63.88
|
-67.22
|
-69.93
|
-78.17
|
-85.87
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-51.79
|
-35.58
|
-52.3
|
-41.38
|
-38.83
|
-44.19
|
-64.9
|
-60.21
|
-66.64
|
-65.65
|
-62.08
|
-65.01
|
-69.07
|
-74.96
|
-83.27
|
Net income
1 |
-51.79
|
-35.58
|
-52.3
|
-41.38
|
-38.83
|
-44.19
|
-64.9
|
-60.21
|
-66.64
|
-65.65
|
-61.36
|
-64.61
|
-67.59
|
-74.96
|
-83.27
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.000
|
-0.6900
|
-1.010
|
-0.8000
|
-0.7400
|
-0.7800
|
-1.080
|
-0.9900
|
-1.090
|
-0.8100
|
-0.7189
|
-0.7467
|
-0.7378
|
-0.8633
|
-0.9567
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/2/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/11/23
|
8/3/23
|
10/30/23
|
3/5/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
345
|
377
|
256
|
123
|
191
|
301
|
176
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-47.7
|
-123
|
-157
|
-189
|
-236
|
-246
|
-237
|
ROE (net income / shareholders' equity)
|
-
|
-33.4%
|
-42%
|
-54.2%
|
-137%
|
-268%
|
-149%
|
-228%
|
ROA (Net income/ Total Assets)
|
-
|
-32.2%
|
-38.3%
|
-45.9%
|
-100%
|
-103%
|
-64.6%
|
-
|
Assets
1 |
-
|
184.9
|
389.5
|
366
|
235.7
|
252.3
|
452.4
|
-
|
Book Value Per Share
2 |
-
|
7.530
|
7.140
|
4.860
|
1.530
|
3.050
|
4.110
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.16
|
3.62
|
3.07
|
0.73
|
1.78
|
2.15
|
2.7
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
15.31%
|
5.34%
|
Announcement Date
|
8/25/20
|
3/4/21
|
3/10/22
|
3/2/23
|
3/5/24
|
-
|
-
|
-
|
Average target price
37.8
USD Spread / Average Target +45.38% Consensus |
1st Jan change
|
Capi.
|
---|
| +95.49% | 2.27B | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|